Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA
Category
331 releases
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA
CF Industries Holdings, Inc. Reports First Nine Months 2026 Net Earnings of $1.78 Billion, Adjusted EBITDA of $3.01 Billion
Reported Third Quarter of 2026 Net Income of $8.8 million, Adjusted EBITDA of $38.7 million and Distributable Cash Flow of $21.8 million compared to…
Third Quarter Pre-Tax Income of $116 million
Reports Record Third Quarter Results for Revenue, Gross Profit, Adjusted EBITDA and Net Income
Cirrus Logic Reports Fiscal Second Quarter Revenue of $559.5 Million
Compass Diversified Reports Third Quarter 2026 Financial Results
18% revenue growth, 11% organic revenue growth, and 32% adjusted EPS growth1
Company Drives Significant Increases in Test Volume and Ordering Providers with Florida Becoming Second Medicaid State Covering Test PreTRM® test…
Third quarter revenue increased 14% year-over-year to $1,722 million
Third quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior year
Blue Owl Capital Corporation (NYSE: OBDC) ("OBDC" or the "Company") today announced financial results for its third quarter ended September 30, 2026.…